A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome
NCT01906307
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
6
Enrollment
INDUSTRY
Sponsor class
Stopped
Corporate decision
Conditions
Hepatorenal Syndrome Type I and Type II
Interventions
DRUG:
LJPC-501
Sponsor
La Jolla Pharmaceutical Company